Table 11 List of the repositioning candidates, therapeutic category and the supporting published evidence in \(\#Cluster_4\)
From: Using informative features in machine learning based method for COVID-19 drug repurposing
Candidate drug | Therapeutic category | References |
|---|---|---|
Aldesleukin | Anti-infective agents | [26] |
Dapsone | Anti-infective agents | [51] |
Acetaminophen | Central nervous system agents | [52] |
Celecoxib | Anti-inflammatory agents | [33] |
Rofecoxib | Anti-inflammatory agents | [53] |
Valdecoxib | Anti-inflammatory agents | [54] |
Diclofenac | Anti-inflammatory agents | [55] |
Triamcinolone | Alimentary tract and metabolism | - |
Etoposide | Antineoplastic agents | [56] |
Phenylbutazone | Anti-inflammatory agents | [57] |
Meloxicam | Anti-inflammatory agents | [58] |
Chlorphenesin | Central nervous system agents | [59] |
Ibuprofen | Anti-inflammatory agents | [26] |
Paclitaxel | Antineoplastic agents | - |
Drospirenone | Contraceptive agents, female | [60] |
Antipyrine | Anti-inflammatory agents | - |
Etoricoxib | Anti-inflammatory agents | [53] |
Resveratrol | Anti-inflammatory agents | [61] |
Nimesulide | Anti-inflammatory agents | [62] |
Capsaicin | Sensory system agents | [63] |
Parecoxib | Anti-inflammatory agents | [64] |
Pomalidomide | Antineoplastic agents | [65] |
Cannabidiol | Antidepressive agents | [66] |
Loxoprofen | Anti-inflammatory agents | [67] |
Dexibuprofen | Anti-inflammatory agents | [68] |
Propacetamol | Sensory system agents | [69] |
Venetoclax | Antineoplastic agents | – |
Nabiximols | Central nervous system agents | – |